Jazz Pharmaceuticals

Jazz Pharmaceuticals

Identifying, developing and commercializing meaningful products that address unmet medical needs
Palo Alto United States (HQ)
Deals in the last 12 months undisclosed
Unicorns in portfolio: Celator Pharmaceuticals

Jazz Pharmaceuticals Company information

Edit
Launch date
Employees
2,213 people
Ownership
Market cap
$7.9b
Net debt
$625m
Firm valuation
€7.8b (Public information from 2020)
USD20162017201820192020E2021E2022E
Revenues-1.6b1.9b2.2b2.3b2.5b2.7b
% growth--17 %14 %6 %8 %8 %
EBITDA-908m1.0b1.1b945m1.2b1.4b
% EBITDA margin-56 %55 %52 %41 %51 %54 %
Profit-488m447m523m275m588m730m
% profit margin-30 %24 %24 %12 %24 %27 %
EV / Revenue-5.7x4.6x4.4x3.8x3.2x2.7x
EV / EBITDA-10.2x8.4x8.4x9.1x6.4x4.9x
  • Edit
DateInvestorsAmountRound
N/A$7.1mSERIES A
$250mSERIES B
N/A$108mIPO
$7mPOST IPO EQUITY
N/A$120mPOST IPO DEBT
Total Funding€234m

Recent News about Jazz Pharmaceuticals

Edit
LocationEdit
United States, Palo Alto

Investments by Jazz Pharmaceuticals

Edit
Are you an employee or an investor of this company?
Add your profile